Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1814 • ACR Convergence 2020
The Association of Urinary Membrane Attack Complex (C5b-9) with Proteinuria and Glomerular Activity in Lupus Nephritis
Shudan Wang¹, Erica Moore², Brianna Lally³, Beatrice Goilav⁴, Chaim Putterman³ and Anna Broder⁵, ¹Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, ³Albert Einstein College of Medicine, Bronx, NY, ⁴The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁵Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Complement activation is known to play a major role in lupus nephritis (LN). Urinary membrane attack complex (C5b-9) has been shown to correlate with…
Abstract Number: 1830 • ACR Convergence 2020
Adverse Drug Reactions to Trimethoprim-sulfamethoxazole as a Prophylactic Agent Against Pneumocystis Pneumonia in Patients with Systemic Lupus Erythematosus: anti-Sm Antibody as a Possible Risk Factor
Shinji Izuka¹, Hiroyuki Yamashita², Yuko Takahashi² and Hiroshi Kaneko², ¹Devision of Rheumatic Disease, National Center for Global Health and Medicine, Toshima-Ku, Tokyo, Japan, ²Devision of Rheumatic Disease, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
Background/Purpose: Pneumocystis pneumonia (PCP) is a life-threatening infection in immunocompromised patients, including those with connective tissue diseases (CTDs), treated with corticosteroids or immunosuppressive agents. Trimethoprim-sulfamethoxazole…
Abstract Number: 1951 • ACR Convergence 2020
Possible Involvement of Fractalkine/CX3CR1 Axis in Peripheral CD14++CD16+ Monocytes in Disease Development of Patients with Systemic Lupus Erythematosus
Keiko Yoshimoto¹, Katsuya Suzuki¹, Noriyasu Seki², Shuntaro Saito³, Jun Kikuchi¹ and Tsutomu Takeuchi⁴, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁴Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan
Background/Purpose: Fractalkine (FKN) binds its receptor, CX3CR1 and accelerates chemotaxis of immune cells by inducing cell surface molecules and mediating adhesion of the cells to…
Abstract Number: 0251 • ACR Convergence 2020
Dynamics of Anti-Nuclear Antibodies in a Longitudinal Study of a Large Systemic Lupus Erythematosus Cohort
May Choi¹, Marvin Fritzler², Karen Costenbader³, Murray Urowitz⁴, John Hanly⁵, Caroline Gordon⁶, Yvan St. Pierre⁷, Sang-Cheol Bae⁸, Juanita Romero-Díaz⁹, F Jorge Sanchez-Guerrero¹⁰, Sasha Bernatsky¹¹, Daniel Wallace¹², David Isenberg¹³, Anisur Rahman¹⁴, Joan Merrill¹⁵, Paul Fortin¹⁶, Dafna Gladman¹⁷, Ian Bruce¹⁸, Michelle Petri¹⁹, Ellen M Ginzler²⁰, Mary Anne Dooley²¹, Rosalind Ramsey-Goldman²², Susan Manzi²³, Andreas Jönsen²⁴, Graciela Alarcón²⁵, Ronald F Van Vollenhoven²⁶, Cynthia Aranow²⁷, Meggan Mackay²⁸, Guillermo Ruiz-Irastorza²⁹, S. Sam Lim³⁰, Murat Inanc³¹, Kenneth Kalunian³², Søren Jacobsen³³, Christine Peschken³⁴, Diane Kamen³⁵, Anca Askanase³⁶ and Ann Clarke³⁷, ¹Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶University of Birmingham, Birmingham, England, United Kingdom, ⁷McGill University, Montreal, Canada, ⁸Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹⁰University Health Network/Sinai Health system, Toronto, ON, Canada, ¹¹The Research Institute of the McGill University Health Centre, Montreal, ON, Canada, ¹²Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, ¹³Centre for Rheumatology, University College London and Department of Rheumatology, University College Hospital, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, ¹⁶CHU de Quebec - Universite Laval, Quebec, Canada, ¹⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁸Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ¹⁹Johns Hopkins University School of Medicine, Baltimore, ²⁰SUNY Downstate Health Sciences University, Brooklyn, ²¹University of North Carolina, Chapel Hill, NC, ²²Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²³Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²⁴Lund University, Lund, Sweden, ²⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, ²⁶Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²⁷Feinstein Institutes for Medical Research, Manhasset, NY, ²⁸Feinstein Institute for Medical Research, Manhasset, NY, ²⁹Hospital Universitario Cruces, Barakaldo, Spain, ³⁰Emory University, Atlanta, GA, ³¹Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³²University of California San Diego, La Jolla, CA, ³³University of Copenhagen, Copenhagen, Denmark, ³⁴Departments of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ³⁵Medical University of South Carolina, Charleston, SC, ³⁶Columbia University College of Physicians and Surgeons, New York, NY, ³⁷University of Calgary, Calgary, Canada
Background/Purpose: ANA testing as an approach to diagnosing and classifying SLE, now embedded in the EULAR/ACR Criteria, is more important than ever. Cross-sectional studies indicate…
Abstract Number: 0268 • ACR Convergence 2020
Impact of Flares on Healthcare Resource Usage and PROs in Systemic Lupus Erythematosus Patients
Zahi Touma¹, Benjamin Hoskin², Christian Atkinson², David Bell³, James Pike², Jennifer Lofland⁴, Pamela Berry⁵, Chetan Karyekar⁵ and Karen Costenbader⁶, ¹University of Toronto, Toronto, ON, Canada, ²ADELPHI REAL WORLD, Bollington, United Kingdom, ³ADELPHI REAL WORLD, Bollington, Macclesfield, United Kingdom, ⁴Janssen Global Market Access, horsham, PA, ⁵Janssen Global Services, LLC, Horsham, PA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The effect of flares on healthcare resource usage and patient-reported outcome scores in SLE patients is not well quantified.To understand how flares impact healthcare…
Abstract Number: 0285 • ACR Convergence 2020
CXCL13 Neutralization Reduces Neuropsychiatric Manifestations in MRL/lpr Mice
Michelle Huang¹, Ariel Stock¹ and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Targeted treatments for neuropsychiatric systemic lupus erythematosus (NPSLE) remain challenging to develop due to the unclear pathogenesis of the disease. Our laboratory has previously…
Abstract Number: 0302 • ACR Convergence 2020
Longitudinal Study of Acute SLE Flare Reveals Dynamic Changes in Multiple Immune Cell Subsets
Kieran Manion¹, Dennisse Bonilla², Dafna Gladman¹, Murray Urowitz³, Zahi Touma⁴ and Joan Wither², ¹Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: In SLE, periods of relative quiescence are punctuated by flares in disease activity that can lead to extensive tissue damage and morbidity. Existing studies…
Abstract Number: 0498 • ACR Convergence 2020
Exploring the Role of Lipocalin-2 in Neuropsychiatric SLE Pathogenesis
Chaim Putterman¹, Elise Mike¹ and Sayra Garcia¹, ¹Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: While the etiology of neuropsychiatric lupus (NPSLE) is not fully understood, blood brain barrier (BBB) disruption and localized neuroinflammation are potential mechanisms that contribute…
Abstract Number: 0618 • ACR Convergence 2020
The Effect of Travel Burden on Depression and Anxiety in African American Women Living with Systemic Lupus
Trevor Faith¹, Ashley White¹, Aissatou Ba¹, Viswanathan Ramakrishnan², Hetlena Johnson³, Jillian Rose⁴, Clara Dismuke-Greer⁵, Jim Oates⁶, Leonard Egede⁷ and Edith Williams¹, ¹Medical University of South Carolina, Charleston, SC, ²medical university of south carolina, south carolina, ³LupusCSC, Columbia, SC, ⁴Hospital for Special Surgery, New York, ⁵Palo Alto VA, Palo Alto, CA, ⁶Medical University of South Carolina, Charleston, SC, Charleston, SC, ⁷Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: The United States has a deficit of rheumatology specialists. This leads to an increased burden accessing care for patients with autoimmune and connective tissue…
Abstract Number: 0852 • ACR Convergence 2020
How Much Prednisone Is Enough for Remission Induction in Lupus Nephritis? A Propensity Score Matched Analysis
Konstantinos Tselios¹, Dafna Gladman², Haifa Al-Sheikh³, Jiandong Su⁴ and Murray Urowitz¹, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³King Faisal Specialist Hospital and Research Centre, Riyadh, Ar Riyad, Saudi Arabia, ⁴University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada
Background/Purpose: The existing guidelines for remission induction in lupus nephritis (LN) from both the ACR and the EULAR recommend initial prednisone doses of 0.5-1mg/kg/day. However,…
Abstract Number: 0870 • ACR Convergence 2020
Hydroxychloroquine Is Associated with Lower Platelet Activity and Improved Vascular Health in Systemic Lupus Erythematosus
Michael Golpanian¹, Elliot Luttrell-Williams², MacIntosh Cornwell², Khrystyna Myndzar², Hanane El Bannoudi², Ashira Blazer², Stuart Katz², Nathaniel Smilowitz², Kelly Ruggles², Robert Clancy³, Jill Buyon⁴ and Jeffrey Berger², ¹New York University, New York, NY, ²New York University School of Medicine, New York, ³NYU School of Medicine, New York, ⁴Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of premature atherosclerosis and thrombosis. Hydroxychloroquine (HCQ) is widely used in the treatment of…
Abstract Number: 0986 • ACR Convergence 2020
BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus
Victoria Werth¹, Richard Furie², Juanita Romero-Díaz³, Sandra Navarra⁴, Kenneth Kalunian⁵, Ronald van Vollenhoven⁶, Filippa Nyberg⁷, Benjamin Kaffenberger⁸, Saira Sheikh⁹, Goran Radunovic¹⁰, Xiaobi Huang¹¹, Hua Carroll¹², Francois Gaudreault¹², Adam Meyers¹¹, Catherine Barbey¹³, Cristina Musselli¹¹ and Nathalie Franchimont¹¹, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁴University of Santo Tomas, Manila, Philippines, ⁵University of California San Diego, La Jolla, CA, ⁶Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁷Karolinska University Hospital, Stockholm, Sweden, ⁸Ohio State University, Columbus, OH, ⁹Division of Rheumatology, Allergy and Immunology, University of North Carolina, Chapel Hill, NC, ¹⁰Institute of Rheumatology, University of Belgrade, Belgrade, Serbia, ¹¹Biogen, Cambridge, MA, ¹²Biogen, Cambridge, ¹³Biogen, Baar, Switzerland
Background/Purpose: No approved targeted therapies have been developed for cutaneous lupus erythematosus (CLE), a disfiguring autoimmune disease that severely impairs quality of life.1 BIIB059 is…
Abstract Number: 1131 • ACR Convergence 2020
Patient Perspective of Helpfulness of Lupus Medications: A Qualitative Study of Medication Use Within the Type 1 and 2 SLE Model
Mithu Maheswaranathan¹, Kevin McKenna², Amy Corneli², David Pisetsky³, Megan Clowse⁴ and Amanda Eudy¹, ¹Duke University, Durham, NC, ²Duke University, Durham, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Medication management in systemic lupus erythematosus (SLE) is particularly complex given the clinical heterogeneity of symptoms and a wide range of medications used. We…
Abstract Number: 1267 • ACR Convergence 2020
Perceived Stress During the COVID-19 Pandemic Independently Associates with Worse Patient-Reported Outcomes in Systemic Lupus Erythematosus (SLE)
Sarah Patterson¹, Laura Trupin², Kimberly DeQuattro¹, Cristina Lanata¹, Maria Dall'Era³, Jinoos Yazdany² and Patricia Katz², ¹UCSF, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: Causes and risk factors for variations in SLE disease activity and symptom severity are incompletely understood. Prior studies suggest a link between stressful life…
Abstract Number: 1283 • ACR Convergence 2020
Factors Affecting Mortality of Systemic Lupus Erythematosus Patients in Spain in the 21st Century: Data from the RELESSER Registry
Clara Moriano¹, Jaime Calvo-Alén², Iñigo Rúa-Figueroa³, Elvira Díez Álvarez¹, Cristina Bermúdez⁴, Francisco J López-Longo⁵, Maria Galindo-Izquierdo⁶, Alejandro Olivé-Marqués⁷, Eva Tomero Muriel⁸, Antonio Fernandez-Nebro⁹, Mercedes Freire-González¹⁰, Olaia Fernandez-Berrizbeitia¹¹, Ana Pérez Gómez¹², Maria Esther Uriarte¹³, Carlos Marras Fernández-Cid¹⁴, Carlos Montilla Morales¹⁵, Gregorio Santos Soler¹⁶, Ricardo Blanco¹⁷, Manuel Rodríguez-Gómez¹⁸, Paloma Vela¹⁹, Alina Lucica Boteanu²⁰, Francisco Javier Narváez²¹, Victor Martinez Taboada²², Blanca Hernández Cruz²³, Jose Luis Andreu Sanchez²⁴, Jose A Hernández-Beriain²⁵, Lorena Expósito²⁶, Raul Menor Almagro²⁷, Mónica Ibañez-Barceló²⁸, Ivan Castellvi²⁹, Carlos Galisteo³⁰, Enrique Raya³¹, VE Quevedo-Vila³², Tomás Vázquez³³, J Ibáñez-Ruan³⁴ and Jose Maria Pego-Reigosa³⁵, ¹Complejo Asistencial Universitario de León, León, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, ⁴Research Unit Bioaraba, Vitoria, Spain, ⁵Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Hospital Germans Trias i Pujol, Barcelona, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Madrid, Spain, ⁹University of Malaga, Malaga, Spain, ¹⁰CHU Coruña, Coruña, Spain, ¹¹Basurto University Hospital, Bilbao, Spain, ¹²Hospital Universitario Príncipe Asturias, Alcalá de Henares, Madrid, Spain, ¹³Hospital Universitario Donostia, San Sebastian, Spain, ¹⁴Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ¹⁵Hospital Universitario de Salamanca, Salamanca, Spain, ¹⁶Hospital Marina Baixa, Alicante, Spain, ¹⁷Hospital Universitario Marques de Valdecilla, Santander, Spain, ¹⁸Hospital Complex of Ourense, Ourense, Spain, ¹⁹Hospital General Alicante, Alicante, Spain, ²⁰PRINTO, Istituto Giannina Gaslini, Genova, Italy, ²¹Hospital Bellvitge, BARCELONA, Spain, ²²Marqués de Valdecilla University Hospital, Santander, Spain, ²³Universidad de Sevilla, Sevilla, Spain, ²⁴Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²⁵Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²⁶Hospital Clinico Tenerife, Tenerife, Spain, ²⁷Hospital General Universitario de Jerez de la Frontera, Puerto De Santa Mar�a, Spain, ²⁸Hospital Son Llatzer, Mallorca, Spain, ²⁹Hospital Santa Creu i Sant Pau, Barcelona, Spain, ³⁰Hospital Parc Taulí, Barcelona, Spain, ³¹Hospital San Cecilio, Granada, Spain, ³²Hospital Comarcal de Monforte, Lugo, Spain, ³³Hospital Lucus Augusti, Lugo, Spain, ³⁴Hospital Povisa, Vigo, Pontevedra, Spain, ³⁵University Hospital of Vigo, Galicia Sur Health Research Institute, Vigo, Spain
Background/Purpose: The mortality in Systemic Lupus Erythematosus (SLE) varies largely across different countries most probably due to social, healthcare and ethnic differences.To analyze the causes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].